For decades, the medical community frequently overlooked the physiological complexities of the female reproductive system, often discarding crucial biological tissues as mere medical waste. This systemic neglect created a profound void in scientific understanding, leaving women’s health issues under-researched and poorly managed compared to other fields of medicine. However, Kaitlin Fogg, an assistant professor of bioengineering at Oregon State University, is currently spearheading a transformative movement to rectify these historical imbalances. By integrating advanced engineering principles with reproductive biology, she is establishing a long-overdue framework for investigating diseases that primarily or exclusively affect women. Her research program represents a fundamental shift in perspective, transitioning from a tradition of oversight toward a paradigm where the intricacies of the female body are treated as a central priority for scientific discovery. This change is essential for developing effective treatments and improving the long-term health outcomes for half of the global population.
Throughout her professional career, Fogg has highlighted the stark disparity in baseline biological data between well-funded fields like bone tissue engineering and the under-researched area of gynecological health. While other disciplines benefit from generations of data regarding structural and mineral properties, researchers in ovarian cancer and reproductive health have often lacked basic benchmarks. Fogg’s transition into this space was driven by the realization that this lack of information was a systemic failure rather than a lack of scientific interest. By treating gynecological samples as valuable assets rather than disposable byproducts, her lab is filling these critical knowledge gaps and creating a foundation for future medical breakthroughs. This dedication to data collection is not just about academic curiosity; it is a necessary step toward building the diagnostic tools and therapies that have been missing from clinical practice for generations, ensuring that reproductive health receives the same level of scientific rigor as any other major biological system.
Revolutionizing Tissue Engineering Through “Layer Cake” Models
Advanced 3D Scaffolding and Vascularization Techniques: The Structural Base
To bridge the gap in understanding, the Fogg Lab has developed a pioneering methodology for creating functional, three-dimensional models of tissues such as the cervix, endometrium, and vaginal epithelium. Fogg utilizes a “layer cake” metaphor to describe the architectural complexity of these engineered tissues, which rely on a structured base of hydrogels enriched with collagen and other essential proteins. This scaffolding mimics the natural extracellular matrix, providing the necessary mechanical properties and structural cues for living cells to thrive in a controlled environment. Unlike traditional cell cultures that grow in flat, two-dimensional layers, these hydrogel systems allow for the recreation of the physical stresses and spatial orientations found within the human body. By meticulously engineering the stiffness and composition of these scaffolds, the team can simulate how healthy tissue behaves and identify the exact moment when pathological changes, such as the onset of fibrotic diseases or early-stage cancerous growths, begin to take root.
A critical innovation in this design is the inclusion of a middle layer filled with vascular cells, which allows the team to observe angiogenesis—the process by which new blood vessels form to support tissue growth. In many gynecological diseases, particularly aggressive cancers, the formation of new blood supply routes is a key driver of disease progression and resistance to treatment. By incorporating these vascular elements into their “layer cake” models, Fogg’s team can study how tumors recruit blood vessels and how this process might be interrupted by new therapeutic agents. This level of physiological relevance is vital for translating laboratory findings into clinical applications, as it provides a much more accurate representation of how a drug or a disease will interact with a living system. The ability to monitor real-time cellular interactions within a vascularized environment marks a significant advancement over previous modeling techniques, offering a robust platform for testing interventions before they reach human trials.
Replicating Biological Barriers and Cellular Interactions: The Functional Top
The final layer of these models, known as the “epithelial icing,” consists of specific cells relevant to the tissue being studied, serving as the biological barrier that interacts with the external environment. This top layer is incredibly sophisticated, representing the primary line of defense against pathogens and the main surface through which many localized treatments are absorbed. In the Fogg Lab, researchers populate this layer with specialized cells such as endometrial or vaginal epithelial cells, creating a functional interface that mimics the real-world behavior of gynecological organs. This 3D architecture allows the team to observe cellular behavior and tissue responses with a degree of accuracy that traditional 2D cell cultures simply cannot achieve. By replicating the physical and chemical environment of the female reproductive system, these models provide a high-fidelity platform for studying how diseases like cancer metastasize and how chronic conditions develop within the body over time.
Beyond merely providing a static representation of tissue, these models allow for the observation of complex cellular cross-talk, which is essential for understanding how different cell types coordinate their responses to stress or infection. For instance, the interaction between the epithelial “icing” and the underlying vascular “filling” can reveal how inflammatory signals travel through the tissue and affect distant organs. This holistic approach to tissue engineering enables the researchers to identify potential drug targets that might be invisible in simpler, non-layered systems. By focusing on the synergy between different cell populations, the Fogg Lab is uncovering the mechanisms behind tissue repair and degeneration. This research is particularly relevant for conditions where the barrier function is compromised, leading to chronic inflammation or increased susceptibility to infection, providing a clear pathway toward developing more effective topical and systemic treatments for a wide range of reproductive health issues.
Redefining Pharmacology and Public Health Standards
Evaluating Hormonal Impacts on Drug Metabolism: The 28-Day Simulation
A cornerstone of Fogg’s research, supported by a significant NIH award, is the investigation of how the menstrual cycle influences drug delivery and efficacy. For decades, clinical research often ignored hormonal fluctuations, leading to a “one-size-fits-all” approach that failed to account for the dynamic nature of women’s physiology. By simulating a 28-day menstrual cycle within her tissue models—adjusting levels of estrogen, progesterone, and luteinizing hormone—Fogg is able to observe how the permeability of the epithelial barrier changes. This research suggests that hormonal phases play a major role in how medications are metabolized, potentially leading to more personalized and effective treatments for female patients. The team has discovered that the barrier can become significantly more or less permeable depending on the specific time of the month, which has massive implications for the dosing of medications delivered orally, topically, or through the vaginal route.
Furthermore, this work challenges the traditional pharmaceutical industry to move toward a model of personalized medicine that considers the patient’s hormonal status as a vital variable. By demonstrating that drug absorption is not a constant value but a fluctuating one, the Fogg Lab is providing the evidence necessary to update clinical trial protocols and drug labeling instructions. This shift is essential for ensuring that women receive the therapeutic benefits of medications while minimizing the risk of adverse side effects caused by improper dosing during specific phases of their cycle. The ability to predict these changes using bioengineered models offers a cost-effective and ethical alternative to large-scale human testing during early drug development. Ultimately, this research aims to eliminate the guesswork in prescribing medications for women, ensuring that healthcare providers can offer data-driven recommendations that respect the unique biological rhythms of the female body throughout its reproductive lifespan.
Investigating Toxicology and Environmental Health: Public Safety and Chronic Care
Beyond drug delivery and oncology, the Fogg Lab is expanding its scope to include the toxicology of common menstrual products and the impact of environmental pollutants. In collaboration with other researchers, Fogg is examining how nanoplastics shed from tampons and menstrual cups might trigger inflammatory responses in sensitive tissues. This work is essential for consumer safety and could influence future manufacturing regulations, as there is currently very little oversight regarding the long-term cellular effects of these materials. By exposing their bioengineered models to the chemical and physical components of these products, the team can identify potential risks before they manifest as widespread health crises. This proactive approach to environmental health ensures that the products used by millions of people every day are held to the highest safety standards, reflecting a commitment to public health that transcends traditional academic research.
Additionally, the lab utilizes its models to study endometriosis, a chronic condition affecting millions, to better understand why uterine-like tissue grows in abnormal locations and how it interacts with the rest of the body. Endometriosis is notoriously difficult to diagnose and treat, often taking years for patients to receive proper care due to a lack of understanding of its underlying mechanisms. Fogg’s research focuses on how these ectopic tissues establish their own blood supply and interact with the immune system, providing new insights into the inflammatory pathways that drive the disease. By modeling these interactions in a controlled laboratory setting, the team is identifying new therapeutic targets that could alleviate chronic pain and improve fertility for those living with the condition. This comprehensive research agenda demonstrates the power of bioengineering to solve real-world problems, moving the field of women’s health toward a future where every condition is met with rigorous scientific inquiry and innovative technical solutions.
The research conducted by Kaitlin Fogg and her team at Oregon State University established a new standard for the inclusion of female-specific physiology in modern engineering. By developing sophisticated tissue models and securing critical federal funding, the lab successfully addressed the historical data gap that previously hindered medical progress in gynecological health. These efforts provided a scientific foundation that moved the industry away from viewing female biological samples as waste, instead recognizing them as vital components of medical advancement. Furthermore, the commitment to mentoring a diverse generation of future engineers ensured that these research priorities would persist in the scientific community. The findings from these studies suggested that personalized, hormone-aware medical treatments were not only possible but necessary for equitable healthcare. This work laid the groundwork for future innovations in drug delivery, oncology, and environmental safety, providing actionable data that helped clinicians and manufacturers improve outcomes for patients globally.
